clinical trials - 2/23

Entry	Author	Date	Location
Stromedix Chief, After Reloading the Company Treasury, Sets Sight on Trial for Deadly Lung Disease	Ryan McBride	02/07/11	Boston
Clinical Data Stock Surging on FDA Approval of Anti-Depression Drug	Ryan McBride	01/24/11	Boston
Plexxikon, Roche Drug Extends Lives in Patients With Deadly Skin Cancer	Luke Timmerman	01/19/11	San Francisco
Ariad Pharma Stock Up More than 25 Percent on Positive Phase III Data	Ryan McBride	01/18/11	Boston
Allon Starts Trial for Brain Disease	Luke Timmerman	01/06/11	Seattle
Syndax Pharma Study Offers Clues that Lung Cancer Treatment Could Benefit Subset of Patients	Ryan McBride	12/10/10	Boston
Seattle Genetics, Millennium’s Encore: Souped-Up Antibody Looks Better in 2nd Trial	Luke Timmerman	12/07/10	Seattle
Glaxo Ends Resveratrol Drug Study	Ryan McBride	12/01/10	Boston
Pearl Therapeutics, Fresh Off Big VC Round, Tops $3B Lung Drug in Head-to-Head Trial	Luke Timmerman	12/01/10	San Francisco
Sangart Looks to Fund More Human Trials of its Oxygen-Carrying Blood Adjunct	Bruce V. Bigelow	11/17/10	San Diego
Anthera, On a Lean Budget, Seeks to Tap Big Heart Attack Market By Blocking Inflammation	Luke Timmerman	11/16/10	San Francisco
Ambit Files for IPO, Arena Pharmaceuticals Says Weight-Loss Drug on Track, ESRI Launches Medical Place History Map App, & More San Diego Life Sciences News	Bruce V. Bigelow	11/12/10	San Diego
Optimer Halts Study After Antibiotic for Traveler’s Diarrhea Linked to Rash; Shares Drop	Luke Timmerman	11/10/10	San Diego
Dana-Farber and Bay-Area Startup File Responses in Lawsuit Over Rights to Cancer Molecule	Ryan McBride	11/10/10	Boston
Hyperion Hits Goal in Trial for Rare-Disease Drug, Prepping FDA Application	Luke Timmerman	11/03/10	San Francisco
Ironwood Passes 4th Big Trial	Luke Timmerman	11/01/10	Boston
Antigenics Expands Experimental Cancer Treatment, Novartis Adds to Cambridge Presence, Boston Scientific Sells Unit to Stryker, & More Boston-Area Life Sciences News	Erin Kutz	10/29/10	Boston
Triangulation: How Universities, Government, and Business Can Stir More Innovation	Regis Kelly	10/28/10	San Francisco
Omeros Nabs $25M from Paul Allen and the State, Immune Design Strikes 1st Big Deal, & More Seattle-Area Life Sciences News	Luke Timmerman	10/28/10	Seattle
Resolvyx and Celtic Ink Dry Eye Deal	Ryan McBride	10/26/10	Boston
Genzyme Cancer Treatment Doubles Remission Rate	Ryan McBride	10/20/10	Boston
Calistoga Starts Mid-Stage Trial	Luke Timmerman	10/19/10	Seattle
Genentech’s Souped-Up Breast Cancer Drug Beats Original Herceptin in Head-to-Head Study	Luke Timmerman	10/08/10	San Francisco
VentiRx Cancer Drug Passes Early Trial	Luke Timmerman	10/04/10	San Diego
ZymoGenetics Melanoma Drug Shows Survival Data, Adding More Juice to Bristol’s Pipeline	Luke Timmerman	09/29/10	Seattle
ProNAi Therapeutics Advances Gene-Silencing Cancer Drug, Marina Biotech Provides Delivery Package	Ryan McBride	09/28/10	Detroit
Seattle Genetics, Millennium Generate “Dream” Data With Empowered Antibody Drug for Cancer	Luke Timmerman	09/27/10	Seattle
Rigel Arthritis Drug Passes Trial	Luke Timmerman	09/23/10	San Francisco
Biogen Rival Reaches Finish Line with Oral Drug for MS	Ryan McBride	09/22/10	Boston
Zalicus, Formerly the Bicoastal Biotech CombinatoRx, Seeks New Identity with Name Fit for a Warrior	Ryan McBride	09/20/10	Boston
Page 2 of 8	« previous page · next page »

Entry

Author

Date

Location

Stromedix Chief, After Reloading the Company Treasury, Sets Sight on Trial for Deadly Lung Disease

Ryan McBride

02/07/11

Boston

Clinical Data Stock Surging on FDA Approval of Anti-Depression Drug

Ryan McBride

01/24/11

Boston